MedPath

Efficacy and safety assessment of Centella asiatica as a herbal dietary supplement to reduce blood sugar levels in type 2 diabetes patients in Thailand

Phase 2
Recruiting
Conditions
Adult patients with type II diabetes mellitus
Diabetes Mellitus, Non-Insulin-Dependent
Registration Number
TCTR20221219003
Lead Sponsor
(in process) the Royal College of Physicians of Thailand
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
80
Inclusion Criteria

1). Age 18-65 years 2). Willing to participate the study 3). Hemoglobin A1C >6.5% or fasting blood sugar >125 mg/d

Exclusion Criteria

1).Pregnancy or breastfeeding 2).Type I diabetes mellitus 3).Hypo- or hyperthyroidism 4).Severe hepatic diseases 5).Severe renal disease 6).Allergic to Centella asiatica 7).Currently treated with injected insulin

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Hemoglobin A1C 12 weeks percent
Secondary Outcome Measures
NameTimeMethod
Fasting blood sugar 12 weeks mg/dL,Cytokine (TNF-alpha, IFN-gamma, IL-4, IL-10) 12 weeks pg/mL,Liver function test (AST, ALT) 12 weeks IU/L,Serum creatinine 12 weeks mg/dL,Clinical adverse reactions 12 weeks Clinical adverse reactions,Lipid profile 12 weeks mg/d
© Copyright 2025. All Rights Reserved by MedPath